JP4723320B2 - 血中レプチン濃度上昇剤 - Google Patents
血中レプチン濃度上昇剤 Download PDFInfo
- Publication number
- JP4723320B2 JP4723320B2 JP2005256553A JP2005256553A JP4723320B2 JP 4723320 B2 JP4723320 B2 JP 4723320B2 JP 2005256553 A JP2005256553 A JP 2005256553A JP 2005256553 A JP2005256553 A JP 2005256553A JP 4723320 B2 JP4723320 B2 JP 4723320B2
- Authority
- JP
- Japan
- Prior art keywords
- blood
- concentration
- diabetes
- insulin
- leptin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008280 blood Substances 0.000 title claims description 37
- 210000004369 blood Anatomy 0.000 title claims description 37
- 102000016267 Leptin Human genes 0.000 title claims description 18
- 108010092277 Leptin Proteins 0.000 title claims description 18
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 title claims description 18
- 229940039781 leptin Drugs 0.000 title claims description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 34
- 206010012601 diabetes mellitus Diseases 0.000 claims description 25
- 102000004877 Insulin Human genes 0.000 claims description 17
- 108090001061 Insulin Proteins 0.000 claims description 17
- 229940125396 insulin Drugs 0.000 claims description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 15
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 claims description 15
- FOGRQMPFHUHIGU-UHFFFAOYSA-N Uridylic acid Natural products OC1C(OP(O)(O)=O)C(CO)OC1N1C(=O)NC(=O)C=C1 FOGRQMPFHUHIGU-UHFFFAOYSA-N 0.000 claims description 15
- 239000008103 glucose Substances 0.000 claims description 15
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 11
- 230000003247 decreasing effect Effects 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 description 17
- 102000039446 nucleic acids Human genes 0.000 description 17
- 108020004707 nucleic acids Proteins 0.000 description 17
- 230000000694 effects Effects 0.000 description 12
- 235000013305 food Nutrition 0.000 description 12
- 208000008589 Obesity Diseases 0.000 description 11
- 235000020824 obesity Nutrition 0.000 description 11
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 9
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 9
- 102100027441 Nucleobindin-2 Human genes 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- 206010022489 Insulin Resistance Diseases 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000003914 insulin secretion Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- 230000003579 anti-obesity Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229940035893 uracil Drugs 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 4
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 4
- 229940045145 uridine Drugs 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 230000003178 anti-diabetic effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000021258 carbohydrate absorption Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- -1 enzymes Natural products 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091006277 SLC5A1 Proteins 0.000 description 1
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 235000020827 calorie restriction Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000000512 lipotoxic effect Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013384 milk substitute Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
「バイオテクノロジー事典」(株)シー エム シー、1986年10月9日、第246〜247頁
以下、本発明について詳述する。
Wister Rat雄(250g)を20匹供試した。コントロール区とウリジル酸投与区を作り、1試験区当たり10匹ずつ振り分け標準的な餌(SLC)を与えた。又、照明時間は12時間とした。
Claims (1)
- ウリジル酸のみを有効成分とし、血中レプチン濃度を上昇させ、且つ血中グルコース濃度及び血中インスリン濃度を低下させるものであること、を特徴とするヒト用糖尿病予防及び/又は治療剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005256553A JP4723320B2 (ja) | 2005-09-05 | 2005-09-05 | 血中レプチン濃度上昇剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005256553A JP4723320B2 (ja) | 2005-09-05 | 2005-09-05 | 血中レプチン濃度上昇剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007070253A JP2007070253A (ja) | 2007-03-22 |
JP4723320B2 true JP4723320B2 (ja) | 2011-07-13 |
Family
ID=37932019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005256553A Active JP4723320B2 (ja) | 2005-09-05 | 2005-09-05 | 血中レプチン濃度上昇剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4723320B2 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4778946B2 (ja) * | 2007-12-03 | 2011-09-21 | 明治飼糧株式会社 | 血中尿酸値低下剤 |
JP5426918B2 (ja) * | 2009-04-20 | 2014-02-26 | 株式会社 伊藤園 | ウリジンを含有する抗疲労剤又は体力向上剤 |
WO2016008603A1 (en) * | 2014-07-16 | 2016-01-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Food intake, body weight and glucose metabolism regulation by modulation of p2y6 receptor signaling |
EP3002010A1 (en) * | 2014-09-30 | 2016-04-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Food intake, body weight and glucose metabolism regulation by modulation of P2Y6 receptor signaling |
CN115227706B (zh) * | 2022-06-08 | 2023-12-29 | 陈玉松 | 5’-单磷酸核苷酸组合物在制备消脂减肥功能食品和药物中的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08289783A (ja) * | 1995-04-20 | 1996-11-05 | Hokuren Federation Of Agricult Coop:The | α−グルコシダーゼ阻害剤、それを含む糖を主体とする組成物、甘味料、食品及び飼料 |
JP2000319185A (ja) * | 1999-03-10 | 2000-11-21 | Yamasa Shoyu Co Ltd | 脂質代謝調整剤およびその用途 |
JP2002277474A (ja) * | 2001-03-14 | 2002-09-25 | Sanyo Chem Ind Ltd | 血液中のホルモン定量方法 |
JP2003038187A (ja) * | 2001-07-31 | 2003-02-12 | Morinaga & Co Ltd | ネコ肥満遺伝子、その遺伝子産物とその製造法 |
JP2004535378A (ja) * | 2001-04-09 | 2004-11-25 | チロン コーポレイション | グアニジノ化合物 |
JP2004538281A (ja) * | 2001-07-18 | 2004-12-24 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作動薬としての架橋ピペリジン誘導体 |
-
2005
- 2005-09-05 JP JP2005256553A patent/JP4723320B2/ja active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08289783A (ja) * | 1995-04-20 | 1996-11-05 | Hokuren Federation Of Agricult Coop:The | α−グルコシダーゼ阻害剤、それを含む糖を主体とする組成物、甘味料、食品及び飼料 |
JP2000319185A (ja) * | 1999-03-10 | 2000-11-21 | Yamasa Shoyu Co Ltd | 脂質代謝調整剤およびその用途 |
JP2002277474A (ja) * | 2001-03-14 | 2002-09-25 | Sanyo Chem Ind Ltd | 血液中のホルモン定量方法 |
JP2004535378A (ja) * | 2001-04-09 | 2004-11-25 | チロン コーポレイション | グアニジノ化合物 |
JP2004538281A (ja) * | 2001-07-18 | 2004-12-24 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作動薬としての架橋ピペリジン誘導体 |
JP2003038187A (ja) * | 2001-07-31 | 2003-02-12 | Morinaga & Co Ltd | ネコ肥満遺伝子、その遺伝子産物とその製造法 |
Also Published As
Publication number | Publication date |
---|---|
JP2007070253A (ja) | 2007-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101562271B1 (ko) | 알콜대사를 완화하고 알콜유도성 질환의 위험을 감소하기위한 조성물 | |
CA2680751C (en) | Use of dioxabicyclo[3.3.0]octane derivatives as anti-fatigue agents | |
JP5421512B2 (ja) | D−プシコースの血糖上昇抑制効果の利用 | |
KR20150145262A (ko) | 에너지 소비의 촉진 및/또는 에너지 소비 기능 저하의 치료 및/또는 예방제, 또는 방법 | |
JPH0283320A (ja) | 腫瘍予防剤 | |
JP4723320B2 (ja) | 血中レプチン濃度上昇剤 | |
KR101695848B1 (ko) | 진세노사이드 f2를 포함하는 비알코올성 간 질환 또는 인슐린 저항성의 예방 또는 치료용 조성물 | |
WO2021024801A1 (ja) | 軟骨再生促進用組成物 | |
JP2007269631A (ja) | 中性脂肪蓄積抑制剤 | |
JP2007051135A (ja) | D−アロースの血糖上昇抑制効果の利用 | |
JP2017507148A (ja) | 活性化ダイズさや繊維 | |
TWI465245B (zh) | Peptides with antidiabetic effect and their use | |
JP4778946B2 (ja) | 血中尿酸値低下剤 | |
JP7332489B2 (ja) | ホスホジエステラーゼ3阻害用組成物及び血小板凝集抑制用組成物 | |
JP5394644B2 (ja) | アスペルロシドまたはその類縁体を含む筋肉増強剤 | |
KR100732614B1 (ko) | 복어 추출물을 포함하는 비만 또는 당뇨성 질환의 예방또는 치료용 약학 조성물 | |
CN115867289A (zh) | 含有nr及/或nmn与芝麻素类的组合物 | |
CN115867270A (zh) | 烟酰胺腺嘌呤二核苷酸(nad)浓度上升剂 | |
JP2021078397A (ja) | 脂質減少促進剤 | |
JP2009062348A (ja) | ケナフ類(ケナフ、ローゼル)の種子成分による血糖値低下作用及び血糖値上昇抑制作用 | |
JP4300753B2 (ja) | 貧血抑制剤及び食欲抑制剤 | |
WO2020158415A1 (ja) | オレキシン受容体拮抗阻害用組成物 | |
JP2004201675A (ja) | 糖尿病予防効果を有する亜鉛高含有食品 | |
WO2019054396A1 (ja) | フソバクテリウム属細菌および/またはステレラ属細菌の菌数抑制剤 | |
JP2004215562A (ja) | 飲食物用添加剤、医薬組成物、glut4トランスロケート剤及びトランスロケート方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090407 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090601 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090603 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090630 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090827 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090827 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091006 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091224 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100310 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100402 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101012 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101210 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110315 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110407 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140415 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4723320 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140415 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |